Novo Nordisk Annual Report 2021
Contents Introducing Novo Nordisk
Strategic Aspirations
Key risks Management
Consolidated statements
Additional information
Novo Nordisk Annual Report 2021
46
11
Independence and meeting attendance overview
Name
Independence²
Meeting attendance in 20211
Board of
Directors
Chair
Committee
Audit
Committee
Nomination
Committee
Remuneration
Committee
R&D
Committee
Helge Lund
Jeppe Christiansen
Laurence Debroux
Andreas Fibig
Sylvie Grégoire
Mette Bøjer Jensen
Kasim Kutay
Anne Marie Kverneland
Martin Mackay
Henrik Poulsen
Thomas Rantzau
Stig Strøbæk
Independent
Not independent 3
Independent 4,5,8
Independent 4
Independent 4
Not independent 6
Not independent 3
Not independent 6
Independent
Not independent 3,4,5,8
Not independent 6
Not independent 4,6
Board members who stepped down at the annual general meeting in March 2021
Brian Daniels
Liz Hewitt
Independent
Independent
..
1. Number of meetings attended by each Board member out of the total number of meetings within the member's term 2. In accordance with recommendation 3.2.1 of the Danish Corporate Governance Recommendations as designated by Nasdaq Copenhagen 3. Member of
the board of directors or executive management of Novo Holdings A/S 4. Pursuant to the US Securities Exchange Act, Ms Debroux, Mr Fibig and Ms Grégoire qualify as independent Audit Committee members, while Mr Poulsen and Mr Strøbæk rely on an exemption from the
independence requirements 5. Ms Debroux and Mr Poulsen possess the qualifications within accounting and auditing required under part 8 of the Danish Act on Approved Auditors and Audit Firms 6. Elected by employees of Novo Nordisk 7. Collectively the members have relevant
industry expertise 8. Designated as financial experts as defined by the US Securities and Exchange Commission (SEC)View entire presentation